Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(20):1502-1504; doi:10.1093/jnci/90.20.1502
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nelson, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

BRCA2 Research Is On a Fast Track to The Clinic

One of the lessons from tumor suppressor research is that many years usually elapse between the cloning of a gene and identifying its function. Translating the gene's function into effective therapy is even more difficult. At this point, however, the breast cancer susceptibility gene BRCA2 seems to be the exception to that norm.

Even though the first breast cancer susceptibility gene, BRCA1, was cloned more than a year before BRCA2, scientists seem to be having a much easier time trying to figure out the function of BRCA2's protein. Furthermore, what is being discovered about its function has led to several ideas for . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?